Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Conditions
Attention-Deficit/Hyperactivity Disorder
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Center for Clinical Trials, Inc., Saraland, Alabama, United States
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
Advanced Research Center (ARC), Inc., Anaheim, California, United States
Sun Valley Research Center, Imperial, California, United States
Alliance Research, Long Beach, California, United States
IMMUNOe Research Centers, Centennial, Colorado, United States
Luna Research Center, Coral Gables, Florida, United States
Sarkis Clinical Trials, Gainesville, Florida, United States
Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States
Avantis Clinical Research LLC, Miami, Florida, United States
Hope Research Network, LLC., Miami, Florida, United States
Medical Research Group of Central Florida, Orange City, Florida, United States
Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States
APG Research LLC, Orlando, Florida, United States
D&H Tamarac Research Center, Tamarac, Florida, United States
Pediatric Neurology and Epilepsy Specialists, Winter Park, Florida, United States
Advanced Discovery Research LLC, Atlanta, Georgia, United States
Clinical Integrative Research Center of Atlanta, Atlanta, Georgia, United States
CenExcel iResearch, LLC, Decatur, Georgia, United States
CenExel iResearch, LLC., Savannah, Georgia, United States
Qualmedica Research, LLC., Evansville, Indiana, United States
Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States
Qualmedica Research, LLC., Owensboro, Kentucky, United States
DelRicht Research (Touro Medical Center), New Orleans, Louisiana, United States
DelRicht Research, Prairieville, Louisiana, United States
Kennedy Krieger Institute, Baltimore, Maryland, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
Precise Research Centers, Flowood, Mississippi, United States
Clinical Research of Southern Nevada, LLC., Las Vegas, Nevada, United States
Med Clinical Research, Irvington, New Jersey, United States
Jersey Shore University Medical Center, Neptune City, New Jersey, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Duke University, Durham, North Carolina, United States
Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States
CincyScience, West Chester, Ohio, United States
Cyn3rgy Research, Gresham, Oregon, United States
Penn State Health Medical Group - Psychiatry and Behavioral Health, Hershey, Pennsylvania, United States
Coastal Carolina Research Center, North Charleston, South Carolina, United States
Coastal Pediatric Research, Summerville, South Carolina, United States
Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
Houston Clinical Trials, LLC., Bellaire, Texas, United States
Javara, Dallas, Texas, United States
AIM Trials, LLC, Plano, Texas, United States
Family Psych of The Woodlands, The Woodlands, Texas, United States
Clinical Research Partners, LLC, Petersburg, Virginia, United States
Virginia Commonwealth University, Virginia Treatment Center for Children, Richmond, Virginia, United States
Study leads
Jonathan Rubin, MD, MBA
Study Director
Supernus Pharmaceuticals, Inc.